Neuroprotective Effect of Kaempferol against a 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Mouse Model of Parkinson's Disease

被引:116
作者
Li, Shen [1 ,2 ]
Pu, Xiao-Ping [1 ,2 ]
机构
[1] Peking Univ, Natl Key Res Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
[2] Peking Univ, Dept Mol & Cellular Pharmacol, Sch Pharmaceut Sci, Beijing 100191, Peoples R China
关键词
kaempferol; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; neuroprotection; oxidative stress; Parkinson's disease; LOW-DENSITY-LIPOPROTEIN; OXIDATIVE STRESS; MPTP MODEL; DOPAMINERGIC NEUROTOXICITY; MONOAMINE-OXIDASE; CELL-DEATH; NEURONS; 6-HYDROXYDOPAMINE; MECHANISMS; RATS;
D O I
10.1248/bpb.34.1291
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the present study, we investigated the neuroprotective effects of kaempferol in the mouse model of Parkinson's disease, which was induced by neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). We confirmed that MPTP led to behavioral deficits, depletion of dopamine and its metabolites, reduction in superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX) activity, and the elevation of malondialdehyde (MDA) levels in the substantia nigra. When administered prior to MPTP, kaempferol improved motor coordination, raised striatal dopamine and its metabolite levels, increased SOD and GSH-PX activity, and reduced the content of MDA compared with mice treated with MPTP alone. Immunohistochemical studies using anti-tyrosine hydroxylase (TH) antibody showed that medication of kaempferol could prevent the loss of TH-positive neurons induced by MPTP. Taken together, we propose that kaempferol has shown anti-parkinsonian properties in our studies. More work is needed to explore detailed mechanisms of action.
引用
收藏
页码:1291 / 1296
页数:6
相关论文
共 40 条
[1]   Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats [J].
Ahmad, M ;
Saleem, S ;
Ahmad, AS ;
Ansari, MA ;
Yousuf, S ;
Hoda, MN ;
Islam, F .
HUMAN & EXPERIMENTAL TOXICOLOGY, 2005, 24 (03) :137-147
[2]   THE MPTP MODEL - VERSATILE CONTRIBUTIONS TO THE TREATMENT OF IDIOPATHIC PARKINSONS-DISEASE [J].
BLOEM, BR ;
IRWIN, I ;
BURUMA, OJS ;
HAAN, J ;
ROOS, RAC ;
TETRUD, JW ;
LANGSTON, JW .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1990, 97 (2-3) :273-293
[3]   DOPAMINE RELEASED FROM MESENCEPHALIC TRANSPLANTS RESTORES MODULATION OF STRIATAL ACETYLCHOLINE-RELEASE AFTER NEONATAL 6-HYDROXYDOPAMINE - AN INVITRO ANALYSIS [J].
CARDER, RK ;
JACKSON, D ;
MORRIS, HJ ;
LUND, RD ;
ZIGMOND, MJ .
EXPERIMENTAL NEUROLOGY, 1989, 105 (03) :251-259
[4]  
Filomeni G., 2010, Neurobiology of aging
[5]  
FREEMAN BA, 1982, LAB INVEST, V47, P412
[6]   Parkinson disease Systemic and orofacial manifestations, medical and dental management [J].
Friedlander, Arthur H. ;
Mahler, Michael ;
Norman, Keith M. ;
Ettinger, Ronald L. .
JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 2009, 140 (06) :658-669
[7]   Neuroprotective effects of echinacoside in the mouse MPTP model of Parkinson's disease [J].
Geng, Xingchao ;
Tian, Xuefei ;
Tu, Pengfei ;
Pu, Xiaoping .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2007, 564 (1-3) :66-74
[8]  
GRAHAM DG, 1979, ARCH PATHOL LAB MED, V103, P359
[9]   Toxic effects of dopamine metabolism in Parkinson's disease [J].
Hattori, Nobutaka ;
Wang, Mei ;
Taka, Hikari ;
Fujimura, Tsutomu ;
Yoritaka, Asako ;
Kubo, Shin-ichiro ;
Mochizuki, Hideki .
PARKINSONISM & RELATED DISORDERS, 2009, 15 :S35-S38
[10]   DOPAMINERGIC NEUROTOXICITY OF 1-METHYL-4-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE IN MICE [J].
HEIKKILA, RE ;
HESS, A ;
DUVOISIN, RC .
SCIENCE, 1984, 224 (4656) :1451-1453